Literature DB >> 24445479

Uricosuric drugs: the once and future therapy for hyperuricemia?

Mary H Bach1, Peter A Simkin.   

Abstract

PURPOSE OF REVIEW: Although uricosuric agents provide the most time-honoured approach to the control of hyperuricemia, their place in the armamentarium has been eclipsed by that of xanthine oxidase inhibitors. This review considers the potential for uricosuric agents from the perspective of recent progress in the understanding of urate transport systems. RECENT
FINDINGS: No new agents have yet become available, but promising new drugs are under development. Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia.
SUMMARY: Conceptually, modest inhibition of renal tubular reabsorption should provide effective relief for the millions of individuals who are now hyperuricemic and who suffer from its principal consequence, gout.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445479     DOI: 10.1097/BOR.0000000000000035

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  19 in total

Review 1.  Lesinurad: A Review in Hyperuricaemia of Gout.

Authors:  Emma D Deeks
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

2.  Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.

Authors:  Pinky Dua; Rachel Gurrell; Simon Kirby; Maria Sudworth; Peter T Loudon
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

Review 3.  Purines: forgotten mediators in traumatic brain injury.

Authors:  Edwin K Jackson; Detlev Boison; Michael A Schwarzschild; Patrick M Kochanek
Journal:  J Neurochem       Date:  2016-02-25       Impact factor: 5.372

4.  The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.

Authors:  Chi-Jung Tai; Chin-Chung Wu; Kun-Tai Lee; Tzyy-Guey Tseng; Hui-Chun Wang; Fang-Rong Chang; Yi-Hsin Yang
Journal:  Clin Pharmacol Ther       Date:  2021-11-17       Impact factor: 6.903

5.  De-crystallization of Uric Acid Crystals in Synovial Fluid Using Gold Colloids and Microwave Heating.

Authors:  Bridgit Kioko; Taiwo Ogundolie; Morenike Adebiyi; Yehnara Ettinoffe; Caleb Rhodes; Brittney Gordon; Nishone Thompson; Muzaffer Mohammed; Biebele Abel; Kadir Aslan
Journal:  Nano Biomed Eng       Date:  2014

6.  A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.

Authors:  Andrew C Nyborg; Chris Ward; Anna Zacco; Benoy Chacko; Luba Grinberg; James C Geoghegan; Ryan Bean; Michaela Wendeler; Frank Bartnik; Ellen O'Connor; Flaviu Gruia; Vidyashankara Iyer; Hui Feng; Varnika Roy; Mark Berge; Jeffrey N Miner; David M Wilson; Dongmei Zhou; Simone Nicholson; Clynn Wilker; Chi Y Wu; Susan Wilson; Lutz Jermutus; Herren Wu; David A Owen; Jane Osbourn; Steven Coats; Manuel Baca
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

7.  Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Authors:  Nicola Dalbeth; Graeme Jones; Robert Terkeltaub; Dinesh Khanna; Jeff Kopicko; Nihar Bhakta; Scott Adler; Maple Fung; Chris Storgard; Scott Baumgartner; Fernando Perez-Ruiz
Journal:  Arthritis Rheumatol       Date:  2017-08-04       Impact factor: 10.995

8.  Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Authors:  Thomas Bardin; Robert T Keenan; Puja P Khanna; Jeff Kopicko; Maple Fung; Nihar Bhakta; Scott Adler; Chris Storgard; Scott Baumgartner; Alexander So
Journal:  Ann Rheum Dis       Date:  2016-11-07       Impact factor: 19.103

9.  Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study.

Authors:  Hyunwook Kim; Seok-Hyung Kim; Ah Ran Choi; Seungkyu Kim; Hoon Young Choi; Hyung Jong Kim; Hyeong-Cheon Park
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

10.  Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.

Authors:  Yunli Zhou; Mi Zhang; Dan He; Xueyuan Hu; Huarong Xiong; Jianyong Wu; Biyue Zhu; Jingqing Zhang
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.